Sun Pharmaceutical Industries Stock Number Of Employees
| SUNPHARMA | 1,799 3.60 0.20% |
Sun Pharmaceutical Industries fundamentals help investors to digest information that contributes to Sun Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sun Stock. The fundamental analysis module provides a way to measure Sun Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sun Pharmaceutical stock.
Sun | Number Of Employees |
Sun Pharmaceutical Industries Company Number Of Employees Analysis
Sun Pharmaceutical's Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Sun Pharmaceutical Number Of Employees | 43 K |
Most of Sun Pharmaceutical's fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sun Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Sun Pharmaceutical Industries is currently employing 43 K people. This is 291.02% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The number of employees for all India stocks is 128.23% lower than that of the firm.
Sun Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sun Pharmaceutical's direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sun Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sun Pharmaceutical by comparing valuation metrics of similar companies.Sun Pharmaceutical is currently under evaluation in number of employees category among its peers.
Sun Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sun Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sun Pharmaceutical's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Sun Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0854 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 4.13 T | ||||
| Shares Outstanding | 2.4 B | ||||
| Shares Owned By Insiders | 55.10 % | ||||
| Shares Owned By Institutions | 26.30 % | ||||
| Price To Book | 6.23 X | ||||
| Price To Sales | 8.61 X | ||||
| Revenue | 484.97 B | ||||
| Gross Profit | 332.24 B | ||||
| EBITDA | 138.36 B | ||||
| Net Income | 95.76 B | ||||
| Cash And Equivalents | 13.87 B | ||||
| Total Debt | 32.74 B | ||||
| Book Value Per Share | 288.72 X | ||||
| Cash Flow From Operations | 121.35 B | ||||
| Earnings Per Share | 46.14 X | ||||
| Target Price | 2043.32 | ||||
| Number Of Employees | 43 K | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 4.31 T | ||||
| Total Asset | 854.63 B | ||||
| Retained Earnings | 501.59 B | ||||
| Working Capital | 264.91 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 854.63 B |
About Sun Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sun Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sun Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sun Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sun Stock Analysis
When running Sun Pharmaceutical's price analysis, check to measure Sun Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sun Pharmaceutical is operating at the current time. Most of Sun Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sun Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sun Pharmaceutical's price. Additionally, you may evaluate how the addition of Sun Pharmaceutical to your portfolios can decrease your overall portfolio volatility.